Opendata, web and dolomites

AFactory SIGNED

THE FUTURE OF FOOD: Disrupting protein production with microalgae

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 AFactory project word cloud

Explore the words cloud of the AFactory project. It provides you a very rough idea of what is the project "AFactory" about.

environmental    presumably    2050    exports    france    ip    industry    boosts    lab    supplements    caters    2018    disruptive    effectiveness    won    onwards    downside    flos    margin    capacity    110    health    space    environment    takes    unlimited    powder    french    commercialization    partnership    kyanos    indirect    ramp    contaminants    sources    drawing    running    safety    initiate    secure    food    unpredictability    expectations    microalgae    cyclotrophy    massive    market    actions    aquae    group    efficient    jeopardizing    award    aphanizomenon    critical    initial    schedule    factory    relies    thanks    afa    survey    share    functional    sold    job    smarter    unprecedented    compact    plant    10    start    people    channels    pilot    full    grow    first    yields    altran    2023    dietary    industrial    devised    supply    billion    line    eliminates    times    prescription    environmentally    companies    infrastructure    healthy    output    dynamics    demand    smei1    fto    inducing    global    microorganisms    protein    ingredients    95    creations    gaining    summit   

Project "AFactory" data sheet

The following table provides information about the project.

Coordinator
KYANOS BIOTECHNOLOGIES 

Organization address
address: 23 AVENUE DE LOMBEZ APT 21 BATIMENT
city: TOULOUSE
postcode: 31100
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Project website http://www.kyanos.bio
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-05-01   to  2019-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    KYANOS BIOTECHNOLOGIES FR (TOULOUSE) coordinator 50˙000.00

Map

 Project objective

'By 2050, providing food for 10 billion people will become critical. Current protein sources cannot scale up without jeopardizing the environment. French start-up Kyanos has developed a disruptive plant-based protein production technology with no environmental downside. Its unlimited supply potential is in line with the food industry requirements. With unprecedented yields, cost effectiveness and health safety conditions, this industrial process, called 'Cyclotrophy' caters for the growing market expectations for healthy, environmentally-friendly products. Cyclotrophy won the Most Novel Protein Process & IT award at the Protein Summit 2018. It boosts the production of microorganisms such as microalgae and eliminates the unpredictability and the contaminants that affect traditional microalgae production. The process relies on smarter, more compact and more efficient production infrastructure and takes 20 times less space for a similar output. A fully functional lab-scale pilot is already running using AFA microalgae (Aphanizomenon flos-aquae). Thanks to a partnership with Altran Group, Kyanos is now about to ramp-up to the industrial scale. The production capacity of the first factory is devised to quickly grow to reach 100 tonnes of AFA microalgae per year by 2023. Kyanos will first target the high-margin dietary supplements market before addressing the massive food-ingredients demand. Drawing on existing distribution channels and health prescription dynamics, the initial product, AFA microalgae powder, will be sold to global health supplements companies. Kyanos will initiate EU distribution from year 2 onwards. In 2023, exports throughout Europe will represent 95% of the production, presumably gaining a 10% market share and inducing up to 110 indirect job creations in France and Europe The objectives of the SMEi1 are: to secure full-scale design for the Cyclotrophy process scale-up; IP, FTO analysis and global market survey to schedule commercialization actions.'

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "AFACTORY" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "AFACTORY" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Dyme (2019)

Dyme gives its users complete control over their financial situation. The Dyme application provides insight into users’ spending and subscriptions, and lets users cancel, negotiate, or switch any cont

Read More  

DeltaQon (2019)

IOT and cloud computing for online medical analysis service platform

Read More  

QTB4AMR (2019)

Utilizing an innovative chemical platform to defeat antimicrobial resistance

Read More